康健集團(03886.HK)向市民提供受「港康碼」認可的深喉唾液核酸檢測
康健集團(03886.HK)公布,配合香港政府即將推出「港版健康碼」,容許通過2019冠狀病毒病核酸檢測的特定人士,豁免隔離14日檢疫往來粵港澳三地的安排,特以950港元向市民提供受「港康碼」認可的深喉唾液核酸檢測。
950港元的費用包括一次醫生評估、深喉唾液核酸檢測及檢測報告。市民可於提交檢測樣本的第二個工作天獲取檢測報告。
康健集團為了支持政府「港康碼」計劃,與「港康碼」認可檢測機構—香港分子病理檢驗中心合作,於7月2日起在旗下40間普通科診所,聯同Dr. Vio & Partners韋予力醫生醫務所3間綜合醫務中心、基督教靈實協會診所、(柏)峰醫務中心及御康醫務中心共同推出符合「港康碼」要求的核酸檢測,又將價格推向較易負擔的水平,希望市民可以在疫情受控下,盡快恢復正常生活。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.